August 11, 2020

Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers

The Epeleuton Phase 2a data was accepted for publication in the peer reviewed Journal of the American Heart Association. The paper can be found here. In […]
October 18, 2017

Afimmune receives a patent allowance for Oral AF102 in the US

Dublin, Ireland, 18th October 2017 – Afimmune (AF), a privately held drug discovery and development company, today announced receipt of allowance for a patent application in […]
April 14, 2016

Afimmune presents late-breaking news abstract on DS102 at the European Association for the Study of the Liver (EASL) International Liver Congress

Dublin, Ireland, 14th April 2016: Afimmune is today presenting a late-breaking news abstract at the annual meeting of the EASL International Liver Congress in Barcelona, Spain […]
December 18, 2015

Afimmune announces successful completion of a Phase I safety study with bioactive lipid DS102

Dublin, Ireland, December 18th, 2015 – Afimmune, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation […]
November 9, 2015

Afimmune obtains a granted patent covering the use of DS102 to treat fatty liver disorders

Dublin, Ireland, November 9th, 2015 – Afimmune, a privately held biopharmaceutical company, announced today that its patent covering the use of bioactive active pharmaceutical ingredient (API) DS102 […]
January 5, 2015

Positive Pre-Clinical Results for Non-Alcoholic Steatohepatitis (NASH)

Afimmune today announced positive results with its anti-fibrotic compound DS102 in preclinical studies which assessed its potential effectiveness for the treatment of non-alcoholic steatohepatitis (NASH). DS102 […]